Abstract: A solar cell and a method for manufacturing the same are discussed. The solar cell includes a semiconductor substrate, a first doped region of a first conductive type, a second doped region of a second conductive type opposite the first conductive type, a back passivation layer having contact holes exposing a portion of each of the first and second doped regions, a first electrode formed on the first doped region exposed through the contact holes, a second electrode formed on the second doped region exposed through the contact holes, an alignment mark formed at one surface of the semiconductor substrate, and a textured surface that is formed at a light receiving surface of the semiconductor substrate opposite the one surface of the semiconductor substrate in which the first and second doped regions are formed.

Abstract: A solar cell and a method for manufacturing the same are discussed. The solar cell includes a semiconductor substrate, a first doped region of a first conductive type, a second doped region of a second conductive type opposite the first conductive type, a back passivation layer having contact holes exposing a portion of each of the first and second doped regions, a first electrode formed on the first doped region exposed through the contact holes, a second electrode formed on the second doped region exposed through the contact holes, an alignment mark formed at one surface of the semiconductor substrate, and a textured surface that is formed at a light receiving surface of the semiconductor substrate opposite the one surface of the semiconductor substrate in which the first and second doped regions are formed.

Abstract: A solar cell and a method for manufacturing the same are discussed.

Abstract: The present disclosure relates to an electrolyte for a lithium secondary battery capable of improving safety and reliability of the lithium secondary battery and a lithium secondary battery comprising the electrolyte. The electrolyte for a lithium secondary battery of the present embodiments comprises a non-aqueous organic solvent, a lithium salt, flame retarding materials of fluoroalkyl ether and phosphazene, and a solvent comprising at least one ester.

Abstract: A solar cell and a method for manufacturing the same are disclosed. The solar cell includes a semiconductor layer containing first impurities, a first portion positioned on a first part of one surface of the semiconductor layer, the first portion being more heavily doped with second impurities different from the first impurities than the semiconductor layer, a second portion positioned on a second part of the one surface of the semiconductor layer, the second portion being more heavily doped with the first impurities than the semiconductor layer, and a third portion positioned between the first portion and the second portion, the third portion having an impurity concentration lower than an impurity concentration of the first portion and an impurity concentration of the second portion.

Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g.

Abstract: A system for the analysis of ECG signals is disclosed. The system may comprise (i) at least one readout channel, configured to receive an analog ECG signal acquired from at least one electrode attached to a body, and to extract an analog measured ECG signal and analog electrode-skin impedance signals; (ii) at least one ADC, configured to convert those extracted analog signals at the readout channel into digital signals; (iii) a digital adaptive filter unit, configured to calculate a digital motion artifact estimate based on said digital versions of the measured ECG signal and the electrode-skin impedance signals; (iv) at least one DAC, configured to convert said digital motion artifact estimate into an analog signal; and (v) a feedback loop for sending said analog motion artifact estimate signal back to the readout channel configured to deduct said analog motion artifact estimate signal from said analog measured ECG signal.

Abstract: An electrolyte for a lithium secondary battery having flame retardancy, low negative electrode interfacial resistance, and excellent high temperature properties and life characteristics, and a lithium secondary battery including the same. An electrolyte for a lithium secondary battery of the present invention may include a non-aqueous organic solvent, a lithium salt, fluorinated ether or phosphazene, and a resistance-improving additive represented as the following chemical formula (1): FSO2—R1—SO2F??[Chemical Formula 1] wherein R1 is a C1-C12 hydrocarbon unsubstituted or substituted with at least one fluorine.

Abstract: An analog signal processor (ASP) application-specific integrated circuit (ASIC) is disclosed. The ACIS can be used for remotely monitoring ECG signals of a subject that has reduced power consumption. In one aspect, the ASIC performs the functions of: ECG signal extraction with high resolution using ECG readout channel, feature extraction using a band-power extraction channel, adaptive sampling the ECG signals using an adaptive sampling analog-to-digital converter, and impedance monitoring for signal integrity using an impedance monitoring channel. These functions enable the development of wireless ECG monitoring systems that have significantly lower power consumption but are more efficient that predecessor systems. In one embodiment, the ASP ASIC consumes 30 ?W from a 2V supply with compression provided by adaptive sampling providing large reductions in power consumption of a wireless ECG monitoring system of which the ASP ASIC forms a part.

Abstract: A flexible portable terminal is provided. The flexible portable terminal includes a folding portion configured to bend at one end of a body of the flexible portable terminal in a direction to a front surface or a rear surface of the flexible portable terminal, a flexible display unit configured to be mounted on the body of the flexible portable terminal, and to bend in the front surface or the rear surface of the flexible portable terminal according to a bending direction of the folding portion, and a sliding portion configured to enable one end of the flexible display unit to slide according to a difference of a compression/tension caused by a difference of an elongation between the folding portion and the flexible display unit when the folding portion is bent.

Abstract: The invention provides methods for preparing an antibody-active agent conjugate. The conjugate comprises an antibody, a cysteine residue of an amino acid motif that can be recognized by an isoprenoid transferase located at or after the carboxy-terminus of the antibody, an isoprenoid unit operably linked to the cysteine residue, and an active agent. The invention also provides a composition comprising the antibody-active agent conjugate prepared by the methods.

Abstract: A current generator is disclosed. An example current generator includes a plurality of current cells connected in parallel, each current cell being connected to a switch. The current generator further includes a first summer configured to sum the output of each current cell of a first subset of the plurality of current cells and a second summer configured to sum the output of each current cell of a second subset of the plurality of current cells. The current generator also includes a combiner configured to combine the outputs of the first and second summers. Further, each switch is switchable according to a sequence to generate a summed output of the current cells at a plurality of quantization levels to generate positive and/or negative alternations of a pseudo-sinusoidal, alternating current.

Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

Abstract: A liquid crystal display including a first over-driving (OD) compensation unit compensating R data at a first OD rate; a second OD compensation unit compensating G data at a second OD rate; and a third OD compensation unit compensating B data at a third OD rate, where the second OD rate is higher than the first OD rate and the third OD rate.

Abstract: A method and device is disclosed for continuously and simultaneously measuring an impedance signal and a biopotential signal on a biological subject's skin. In one aspect, the method includes attaching input and output electrodes to the biological subject's skin and applying a predetermined alternating current having a first frequency to the output electrodes for creating an alternating voltage signal over the input electrodes. The first frequency is above a predetermined minimum frequency. The method also includes measuring an input signal from the input electrodes which includes a biopotential signal and the alternating voltage signal. The method also includes extracting from the input signal the biopotential signal and the alternating voltage signal, and determining the impedance signal from the alternating voltage signal. The alternating voltage signal is extracted by amplifying and demodulating the input signal using a control signal having a frequency equal to the first frequency.

Abstract: The present invention relates to a use of a crude extract, non-polar solvent soluble extract or purified extract of the hardy kiwifruit for the preparation of therapeutic agent for treating and preventing baldness disorder and seborrheic skin disease in human and mammal, and health care food, food additives, feed additives, cosmetic composition comprising the same. The hardy kiwifruit reduced blood DHT level, promoted the formation of hair root in mouse model experiment, and inhibited the falling out of hair and improved seborrheic skin disease of volunteers such as keratigenous skin, seborrhea etc.

Abstract: An electrolyte for the lithium secondary battery having flame retardancy, low negative electrode interfacial resistance, and excellent high temperature properties and life characteristics, and a lithium secondary battery including the same. An electrolyte for lithium secondary battery of the present invention may include a non-aqueous organic solvent, a lithium salt, fluorinated ether or phosphazene, and a resistance-improving additive represented as the following chemical formula (1): RSO2—R1—SO2F??[Chemical Formula 1] wherein R1 is a C1-C12 hydrocarbon unsubstituted or substituted with at least one fluorine.

Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates, as well as methods for making the conjugates and compositions. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

Abstract: The present disclosure relates to an electrolyte for a lithium secondary battery capable of improving safety and reliability of the lithium secondary battery and a lithium secondary battery comprising the electrolyte. The electrolyte for a lithium secondary battery of the present embodiments comprises a non-aqueous organic solvent, a lithium salt, flame retarding materials of fluoroalkyl ether and phosphazene, and a solvent comprising at least one ester.

Abstract: A rapid, infrared spectroscopic method has been developed to assess the efficacy of targeted chemotherapeutics against the structure of the polypeptide target, based on the effect of natural polymorphic sequence variation on the conformation of the protein. This method has an advantage over the current genomics-based screening, as the new method provides a direct readout of the structural, and hence functional, outcome of polymorphisms to the protein region targeted by drugs. It allows rapid measurement of a protein's susceptibility to therapeutic targeted agents, prior to using the drug as treatment in the patient. This method can be used to identify biomarkers for a response for a protein to a drug which can be readily tested, interpreted, and used in a clinical setting.